Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04994132
Registration number
NCT04994132
Ethics application status
Date submitted
9/07/2021
Date registered
6/08/2021
Date last updated
22/04/2024
Titles & IDs
Public title
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
Query!
Scientific title
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)
Query!
Secondary ID [1]
0
0
NCI-2021-06711
Query!
Secondary ID [2]
0
0
ARST2031
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Alveolar Rhabdomyosarcoma
0
0
Query!
Botryoid-Type Embryonal Rhabdomyosarcoma
0
0
Query!
Embryonal Rhabdomyosarcoma
0
0
Query!
Metastatic Embryonal Rhabdomyosarcoma
0
0
Query!
Metastatic Rhabdomyosarcoma
0
0
Query!
Solid Alveolar Rhabdomyosarcoma
0
0
Query!
Spindle Cell Rhabdomyosarcoma
0
0
Query!
Spindle Cell/Sclerosing Rhabdomyosarcoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Sarcoma (also see 'Bone') - soft tissue
Query!
Cancer
0
0
0
0
Query!
Bone
Query!
Cancer
0
0
0
0
Query!
Children's - Other
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Surgery - Biospecimen Collection
Treatment: Surgery - Bone Marrow Aspiration
Treatment: Surgery - Bone Marrow Biopsy
Treatment: Surgery - Bone Scan
Treatment: Surgery - Computed Tomography
Treatment: Drugs - Cyclophosphamide
Other interventions - Dactinomycin
Treatment: Surgery - Magnetic Resonance Imaging
Treatment: Surgery - Positron Emission Tomography
Treatment: Other - Radiation Therapy
Treatment: Drugs - Vincristine Sulfate
Treatment: Drugs - Vinorelbine Tartrate
Treatment: Surgery - X-Ray Imaging
Experimental: Arm A (VAC, VINO-CPO) - Patients receive vincristine sulfate IV on days 1, 8 and 15 of cycles 1-4, 7, 8, 11, and 12, and day 1 of cycles 5, 6, 9, 10, 13, and 14. Patients also receive dactinomycin IV over 1-15 minutes or IVP over 1-5 minutes on day 1 of cycles 1-5, 8-10, and 11-14, and cyclophosphamide IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on weeks 13 and 40.
MAINTENANCE: Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1, 8, and 15, and cyclophosphamide PO on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Patients in both arms undergo CT, MRI, PET, x-ray imaging, and/or bone scan, as well as blood sample collection throughout the trial. Patients may also undergo bone marrow aspiration and/or biopsy as clinically indicated.
Experimental: Arm B (vinorelbine, VAC, VINO-CPO) - Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1 and 8, vincristine sulfate IV on day 15, dactinomycin IV over 1-15 minutes or IVP over 1-5 minutes on day 1 of cycles 1-5 and 8-14, and cyclophosphamide IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo radiation therapy on weeks 13 and 40.
MAINTENANCE: Patients receive vinorelbine tartrate IV over 6-10 minutes on days 1, 8, and 15, and cyclophosphamide PO on days 1-28. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Patients in both arms undergo CT, MRI, PET, x-ray imaging, and/or bone scan, as well as blood sample collection throughout the trial. Patients may also undergo bone marrow aspiration and/or biopsy as clinically indicated.
Treatment: Surgery: Biospecimen Collection
Undergo blood sample collection
Treatment: Surgery: Bone Marrow Aspiration
Undergo bone marrow aspiration
Treatment: Surgery: Bone Marrow Biopsy
Undergo bone marrow biopsy
Treatment: Surgery: Bone Scan
Undergo bone scan
Treatment: Surgery: Computed Tomography
Undergo CT
Treatment: Drugs: Cyclophosphamide
Given IV or PO
Other interventions: Dactinomycin
Given IV
Treatment: Surgery: Magnetic Resonance Imaging
Undergo MRI
Treatment: Surgery: Positron Emission Tomography
Undergo PET
Treatment: Other: Radiation Therapy
Undergo radiation therapy
Treatment: Drugs: Vincristine Sulfate
Given IV
Treatment: Drugs: Vinorelbine Tartrate
Given IV
Treatment: Surgery: X-Ray Imaging
Undergo x-ray imaging
Query!
Intervention code [1]
0
0
Treatment: Surgery
Query!
Intervention code [2]
0
0
Treatment: Drugs
Query!
Intervention code [3]
0
0
Other interventions
Query!
Intervention code [4]
0
0
Treatment: Other
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Event-free survival
Query!
Assessment method [1]
0
0
Will be estimated using the Kaplan-Meier method and will be compared between the two regimens using a log-rank test.
Query!
Timepoint [1]
0
0
Time from randomization to an event defined as disease relapse/progression, second malignancy, or death, whichever occurs first, assessed up to 5 years from study enrollment
Query!
Secondary outcome [1]
0
0
Overall survival
Query!
Assessment method [1]
0
0
Will be estimated using the Kaplan-Meier method and will be compared between the therapy groups using a log-rank test.
Query!
Timepoint [1]
0
0
Time from randomization to death of any cause, assessed up to 5 years from study enrollment
Query!
Secondary outcome [2]
0
0
Radiologic response rate
Query!
Assessment method [2]
0
0
Includes both complete response and partial response. Response Evaluation Criteria in Solid Tumors 1.1 criteria will be used to define complete and partial responses. Will be compared between arms using chi square test.
Query!
Timepoint [2]
0
0
At week 12 after study enrollment
Query!
Secondary outcome [3]
0
0
Incidence of adverse events
Query!
Assessment method [3]
0
0
Adverse events of particular interest including grade 4 hematologic toxicity, grade 2 sinusoidal obstruction syndrome, grade 3 or higher neuropathy and any non-hematologic toxicity that result in delays > 14 days in the delivery of a 21-day cycle of therapy or results in a dose reduction of any chemotherapy drugs.
Query!
Timepoint [3]
0
0
Up to 5 years from study enrollment
Query!
Secondary outcome [4]
0
0
Feasibility and safety assessed by the adverse events, toxicities and treatment delays
Query!
Assessment method [4]
0
0
If more than 40% of patients enrolled in the safety phase experience one or more of the toxicities, the study will be paused, the study team will review the data and determine if an amendment is needed.
Specifically, toxicities of interest include:
Hematological toxicities that delay the administration of subsequent chemotherapy cycles by more than two weeks.
Grade 2 or higher sinusoidal obstruction syndrome.
Grade 3 or higher neuropathy.
Other Grade 3 or higher non-hematological toxicities that delay the administration of subsequent chemotherapy cycles by more than 2 weeks.
Query!
Timepoint [4]
0
0
From study enrollment to completion of the initial 12 weeks of therapy
Query!
Eligibility
Key inclusion criteria
- Patients must be =< 50 years of age at the time of enrollment
- Patients with newly diagnosed RMS of any subtype, except adult-type pleomorphic, based
upon institutional histopathologic classification are eligible to enroll on the study
based upon stage, group, and age, as below. FOXO1 fusion status must be determined by
week 4 (day 28) of therapy. RMS types included under embryonal RMS (ERMS) include
those classified in the 1995 International Classification of Rhabdomyosarcoma (ICR) as
ERMS (classic, spindle cell, and botryoid variants), which are reclassified in the
2020 World Health Organization (WHO) Classification as ERMS (classic, dense and
botryoid variants) and spindle cell/sclerosing RMS (encompassing the historical
spindle cell ERMS variant and the newly recognized sclerosing RMS variant).
Classification of alveolar RMS (ARMS) in the 2020 WHO Classification is the same as in
the ICR and includes classic and solid variants
- ERMS
- Stage 4, group IV, >= 10 years of age
- ARMS
- Stage 4, group IV Patients will be eligible to remain on protocol therapy
based upon stage, group, and age
- Bone marrow metastatic disease is based on morphologic evidence of RMS based on
hematoxylin and eosin (H&E) stains. In the absence of morphologic evidence of marrow
involvement on H&E, patients with bone marrow involvement detected ONLY by flow
cytometry, reverse transcriptase (RT)-polymerase chain reaction (PCR), fluorescence in
situ hybridization (FISH), or immunohistochemistry will NOT be considered to have
clinical bone marrow involvement for the purposes of this study
- Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70
mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows (must be
performed within 7 days prior to enrollment):
- Age; Maximum serum creatinine (mg/dL)
- 1 month to < 6 months; 0.4 mg/dL (male); 0.4 mg/dL (female)
- 6 months to < 1 year; 0.5 mg/dL (male); 0.5 mg/dL (female)
- 1 to < 2 years; 0.6 mg/dL (male); 0.6 mg/dL (female)
- 2 to < 6 years; 0.8 mg/dL (male); 0.8 mg/dL (female)
- 6 to < 10 years; 1 mg/dL (male); 1 mg/dL (female)
- 10 to < 13 years; 1.2 mg/dL (male); 1.2 mg/dL (female)
- 13 to < 16 years; 1.5 mg/dL (male); 1.4 mg/dL (female)
- >= 16 years; 1.7 mg/dL (male); 1.4 mg/dL (female)
- Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (must be performed within
7 days prior to enrollment)
- If there is evidence of biliary obstruction by tumor, then total bilirubin must
be < 3 x ULN for age
- All patients and/or their parents or legal guardians must sign a written informed
consent
- All institutional, Food and Drug Administration (FDA), and National Cancer Institute
(NCI) requirements for human studies must be met
Query!
Minimum age
No limit
Query!
Query!
Maximum age
50
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Patients with evidence of uncontrolled infection are not eligible
- RMS that is considered a second malignancy and previous cancer(s) that were treated
with chemotherapy and/or radiation. Surgical resection alone of previous cancer(s) is
allowed
- Patients with central nervous system involvement of RMS as defined below:
- Malignant cells detected in cerebrospinal fluid
- Intra-parenchymal brain metastasis separate and distinct from primary tumor
(i.e., direct extension from parameningeal primary tumors is allowed).
- Diffuse leptomeningeal disease
- Patients who have received any chemotherapy (excluding steroids) and/or radiation
therapy for RMS prior to enrollment.
- Note: the following exception:
- Patients requiring emergency radiation therapy for RMS. These patients are
eligible, provided they are consented to ARST2031 prior to administration of
radiation
- Note: Patients who have received or are receiving chemotherapy or radiation for
non-malignant conditions (e.g. autoimmune diseases) are eligible. Patients must
discontinue chemotherapy for non-malignant conditions prior to starting protocol
therapy
- Vincristine and vinorelbine are sensitive substrates of CYP450 3A4 isozyme. Patients
must not have received drugs that are moderate to strong CYP3A4 inhibitors and
inducers within 7 days prior to study enrollment
- Female patients who are pregnant since fetal toxicities and teratogenic effects have
been noted for several of the study drugs. A pregnancy test is required for female
patients of childbearing potential
- Lactating females who plan to breastfeed their infants
- Sexually active patients of reproductive potential who have not agreed to use an
effective contraceptive method for the duration of their study participation
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
14/09/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/09/2027
Query!
Actual
Query!
Sample size
Target
118
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Query!
Recruitment hospital [1]
0
0
John Hunter Children's Hospital - Hunter Regional Mail Centre
Query!
Recruitment hospital [2]
0
0
The Children's Hospital at Westmead - Westmead
Query!
Recruitment hospital [3]
0
0
Royal Children's Hospital - Parkville
Query!
Recruitment hospital [4]
0
0
Perth Children's Hospital - Perth
Query!
Recruitment postcode(s) [1]
0
0
2310 - Hunter Regional Mail Centre
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
3052 - Parkville
Query!
Recruitment postcode(s) [4]
0
0
6009 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Alaska
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arizona
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Arkansas
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
California
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Colorado
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Connecticut
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Delaware
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
District of Columbia
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Florida
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Georgia
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Hawaii
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Idaho
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Illinois
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Indiana
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Iowa
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Kentucky
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Louisiana
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Maine
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Maryland
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Massachusetts
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Michigan
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Minnesota
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Mississippi
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Missouri
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Nebraska
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Nevada
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
New Jersey
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
New York
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
North Carolina
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
North Dakota
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Ohio
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
Oklahoma
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Oregon
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
Pennsylvania
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
Rhode Island
Query!
Country [37]
0
0
United States of America
Query!
State/province [37]
0
0
South Carolina
Query!
Country [38]
0
0
United States of America
Query!
State/province [38]
0
0
South Dakota
Query!
Country [39]
0
0
United States of America
Query!
State/province [39]
0
0
Tennessee
Query!
Country [40]
0
0
United States of America
Query!
State/province [40]
0
0
Texas
Query!
Country [41]
0
0
United States of America
Query!
State/province [41]
0
0
Utah
Query!
Country [42]
0
0
United States of America
Query!
State/province [42]
0
0
Vermont
Query!
Country [43]
0
0
United States of America
Query!
State/province [43]
0
0
Virginia
Query!
Country [44]
0
0
United States of America
Query!
State/province [44]
0
0
Washington
Query!
Country [45]
0
0
United States of America
Query!
State/province [45]
0
0
West Virginia
Query!
Country [46]
0
0
United States of America
Query!
State/province [46]
0
0
Wisconsin
Query!
Country [47]
0
0
Canada
Query!
State/province [47]
0
0
Alberta
Query!
Country [48]
0
0
Canada
Query!
State/province [48]
0
0
Manitoba
Query!
Country [49]
0
0
Canada
Query!
State/province [49]
0
0
Nova Scotia
Query!
Country [50]
0
0
Canada
Query!
State/province [50]
0
0
Ontario
Query!
Country [51]
0
0
Canada
Query!
State/province [51]
0
0
Quebec
Query!
Country [52]
0
0
Canada
Query!
State/province [52]
0
0
Saskatchewan
Query!
Country [53]
0
0
Puerto Rico
Query!
State/province [53]
0
0
Caguas
Query!
Country [54]
0
0
Saudi Arabia
Query!
State/province [54]
0
0
Riyadh
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Children's Oncology Group
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Government body
Query!
Name [1]
0
0
National Cancer Institute (NCI)
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This phase III trial compares the safety and effect of adding vinorelbine to vincristine,
dactinomycin, and cyclophosphamide (VAC) for the treatment of patients with high risk
rhabdomyosarcoma (RMS). High risk refers to cancer that is likely to recur (come back) after
treatment or spread to other parts of the body. This study will also examine if adding
maintenance therapy after VAC therapy, with or without vinorelbine, will help get rid of the
cancer and/or lower the chance that the cancer comes back. Vinorelbine and vincristine are in
a class of medications called vinca alkaloids. They work by stopping cancer cells from
growing and dividing and may kill them. Dactinomycin is a type of antibiotic that is only
used in cancer chemotherapy. It works by damaging the cell's deoxyribonucleic acid (DNA) and
may kill cancer cells. Cyclophosphamide is in a class of medications called alkylating
agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the
body's immune response. Vinorelbine, vincristine, dactinomycin and cyclophosphamide are
chemotherapy medications that work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. This trial may have the potential to eliminate rhabdomyosarcoma for a long time or
for the rest of patient's life.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04994132
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Wendy Allen-Rhoades
Query!
Address
0
0
Children's Oncology Group
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04994132
Download to PDF